A Historic Conclusion to the 17th Annual Skin of Color Update!
The 17th Annual Skin of Color Update (SOCU 2026) came to an inspiring conclusion yesterday in New York City, completing three days of unprecedented scholarship, clinical innovation, and community building.
Co-Chairs Andrew F. Alexis, MD, MPH, FAAD, and Eliot F. Battle, MD, along with Program Development Advisor Heather Woolery-Lloyd, MD, FAAD, led attendees through a high-impact final day focused on atypical disease presentations, complex pigmentary conditions, and emerging systemic and procedural frontiers.
“When we started this meeting 17 years ago, our vision was simple yet vital: to elevate care, research, and education for patients with skin of color. Seeing this room filled with clinicians committed to advancing equity and clinical excellence proves how far we have come—and how bright the future is.”
— Andrew F. Alexis, MD, MPH, FAAD
Day 3 at a Glance
The final day delivered rapid-fire “Hot Takes” across three essential clinical tracks:
-
-
Session VII: Recognizing Atypical Presentations in Skin of Color
Key pearls on differentiating discoid lupus (DLE) from LPP on the scalp, identifying “salt-and-pepper” depigmentation as an early sign of systemic sclerosis, recognizing vasculopathic MDA5+ dermatomyositis on the palms, and managing active Acquired Dermal Macular Hyperpigmentation (ADMH).
-
Session VIII: Pigmentary Disorders in Skin of Color
Paradigm shifts in vitiligo repigmentation using topical/oral JAK inhibitors combined with NB-UVB, treating melasma as a photoaged dermal microenvironment disorder, mandatory iron-oxide photoprotection (≥3%) against visible light, and mini-punch grafting for stable segmental vitiligo.
-
Session IX: Emerging Therapeutics & Skin Cancer in Skin of Color
Debunking historical JAK inhibitor fears using long-term extension data (>17,000 patient-years), identifying scar-associated squamous cell carcinoma (SCC) in Black patients (carrying a 40% metastatic rate), addressing acral/mucosal melanoma detection delays, and understanding exosome biostimulatory biology.
-
Below are the detailed daily “Hot Takes” and clinical summaries from each session of Day 3!
Session VII: Recognizing Atypical Presentations in Skin of Color—Expert Insights on Case‑Driven Care
The Big Picture
Connective tissue disorders, granulomatous diseases, and pigmentary conditions frequently present with subtle, atypical, or disfiguring features in patients with skin of color. High clinical index of suspicion, careful physical examination (including scalp, ears, nails, and palms), and precise histopathological correlation are essential to avoid misdiagnosis, prevent permanent scarring, and mitigate systemic morbidity.
Key Pearls
-
- Discoid Lupus Erythematosus (DLE) vs. LPP Misdiagnosis: DLE of the scalp is frequently misdiagnosed as lichen planopilaris (LPP) due to overlapping interface dermatitis on histology. Look for conchal bowl involvement (classic DLE clue) and deep follicular plugging rather than pure perifollicular scale. Anifrolumab is demonstrating rapid disease shutdown in DLE within two months.
-
- Systemic Sclerosis & MDA5 Dermatomyositis Clues: “Salt-and-pepper” depigmentation in scleroderma is often misdiagnosed as vitiligo; always inspect the fingers for distal tightening. High-dose mycophenolate mofetil improves both skin elasticity and pigmentary changes. For painful palmar papules along creases, suspect vasculopathic MDA5+ dermatomyositis, which carries a critical risk for rapidly progressive interstitial lung disease.
-
- Acquired Dermal Macular Hyperpigmentation (ADMH) Step-Wise Protocol: ADMH encompasses lichen planus pigmentosus, erythema dyschromicum perstans, and Riehl’s melanosis (pigmented contact dermatitis, often from hair dyes/PPD). For active inflammatory disease, shut down basal cell vacuolization with pulse dexamethasone (4 mg on Sat/Sun for 3 months) or colchicine. For stable burnt-out dermal pigment, utilize low-dose oral isotretinoin (20 mg daily for 1 year).
-
- Melasma, Oral Tranexamic Acid & Laser Toning Safety: Oral tranexamic acid (325 mg BID) is highly effective for melasma but requires rigorous screening for thromboembolic risk factors (do not combine with estrogen OCPs). When performing low-fluence Q-switched or picosecond laser toning, limit treatments to 5–6 sessions per year to prevent irreversible “confetti” hypopigmentation from cumulative melanocyte toxicity.
Session VIII: Pigmentary Disorders in Skin of Color—Disease Updates, Pearls, and Case‑Based Management
The Big Picture
Pigmentary disorders represent a major clinical and quality-of-life burden in skin of color, requiring clinicians to understand complex immunometabolic and dermal-microenvironment drivers. From breakthrough JAK inhibitor regimens for vitiligo to understanding melasma as a photodamaged dermal field disorder, combination therapies and rigorous visible-light photoprotection are essential for long-term control.
Key Pearls
-
- Vitiligo Disease Burden & JAK Inhibitor Protocols: Quality-of-life impairment from vitiligo is significantly higher in darker skin types (Fitzpatrick IV–VI). While topical ruxolitinib remains first-line, combination therapy with narrowband UVB (NB-UVB) or oral JAK inhibitors (e.g., upadacitinib, povorcitinib, ritlecitinib) markedly accelerates repigmentation. Early pulse oral steroids (e.g., dexamethasone 2–4 mg Sat/Sun for 6 weeks) stabilize rapidly spreading disease.
-
- Melasma as a Photodamaged Dermal Field Disorder: Melasma is not solely a melanocyte-driven problem; chronic UVA and visible light induce senescence in dermal fibroblasts, endothelial cells, and mast cells, which continuously secrete pro-melanogenic paracrine factors. Treatment requires suppressing this altered dermal microenvironment via low-dose oral tranexamic acid, targeted topicals, and tinting agents.
-
- Visible Light & Tinted Sunscreen Requirements: Non-tinted broad-spectrum sunscreens block UVA/UVB but fail to shield against visible light (VL) and high-energy visible (HEV) blue light, which directly stimulate long-lasting opsin-3-mediated hyperpigmentation in skin of color. Sunscreens containing iron oxides (at concentrations ≥3%) are required to prevent pigment relapse.
-
- Surgical Punch Grafting for Recalcitrant Vitiligo: In stable, localized vitiligo (unresponsive to medical therapy for ≥1 year), 1 mm miniature punch grafting offers excellent repigmentation rates (90–100% color match), particularly in pediatric or segmental vitiligo cases.
Session IX: Emerging Therapeutics and Skin Cancer in Skin of Color: JAKs, Exosomes, & Melanoma/NMSC Essentials
The Big Picture
Advancing dermatologic care in skin of color requires expanding access to highly effective targeted systemic therapies like JAK inhibitors by replacing historic safety fears with modern long-term clinical trial evidence, while aggressively combating persistent diagnostic delays in keratinocyte carcinomas and acral/mucosal melanomas.
Key Pearls
-
-
Revisiting JAK Inhibitor Safety & Real-World Data: Modern long-term extension data (>17,000 patient-years) show MACE, VTE, and malignancy rates for JAK1/TYK2 inhibitors are comparable to or lower than baseline moderate-to-severe atopic dermatitis reference cohorts and equivalent to apremilast. The initial Oral Surveillance study suffered from critical design limitations, including mandatory concomitant methotrexate/steroid use, an elderly high-risk rheumatoid arthritis population, and the absence of a placebo arm.
-
JAK Selectivity, Weight Signals & Tissue Penetration: Weight gain observed with certain JAK inhibitors is driven by off-target JAK2/STAT3 inhibition disrupting leptin signaling. Highly selective agents (e.g., ritlecitinib, abrocitinib) spare JAK2 and avoid weight gain. In hidradenitis suppurativa, povorcitinib delivers a >30-hour half-life with high volume of distribution, lingering in tissue for up to 48 hours to target deep nodular inflammation.
-
Disparities & Unique Features of Skin Cancer in Skin of Color: Keratinocyte carcinomas are the most common cutaneous malignancies across populations, but SCC is the #1 skin cancer in Black patients and frequently arises within chronic inflammatory scars (Marjolin’s ulcer in HS, DLE, or chronic ulcers). Scar-associated SCC carries a 40% metastatic rate in Black patients (vs. 4% for UV-induced SCC in white patients). The 5-year melanoma survival rate for Black patients remains dramatically lower (70% vs. 94% in white patients) due to delayed detection of acral lentiginous and mucosal presentations.
-
Exosomes & Biostimulatory Frontiers: Exosomes represent extracellular vesicles carrying microRNA, proteins, and growth factors that facilitate intercellular paracrine signaling. While showing promise for post-procedure healing and alopecia, clinicians must navigate regulatory distinctions between cosmetic topical formulations and investigational injectable cellular therapies.
-
Looking Ahead: Save the Date for SOCU 2027!
As SOCU 2026 comes to a close, the momentum continues! Mark your calendars now for next year’s milestone gathering:
📅 Skin of Color Update 2027
📍 New York City
🗓️ October 22–24, 2027
Thank you to our world-class faculty, sponsors, resident scholars, and attendees who made SOCU 2026 an extraordinary success. Together, we are changing the landscape of dermatologic care.
See you next year in NYC for SOCU 2027!
Read the Day 1 and Day 2 recaps.
AI Editorial Disclosure:
This summary was generated using AI-assisted transcription and synthesis of live presentation recordings from Skin of Color Update 2026 . This content is intended for educational purposes only for healthcare professionals and should not replace clinical judgment.
